Skip to main content
Log in

White Coat Hypertension and Cardiovascular Diseases: Innocent or Guilty

  • Ischemic Heart Disease (D Mukherjee, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review aims to clarify the cardiovascular risk of white coat hypertension (WCH).

Recent Findings

Cardiovascular risk of WCH has been evaluated in multiple meta-analyses and population-based studies. International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes study evaluated the cardiovascular risk in 653 patients with WCH and 5137 normotensive patients. The patients were age-matched and were followed for 10.6 years. The results revealed no increased cardiovascular risk except in older high-risk WCH patients. A recent meta-analysis evaluated the cardiovascular risk in WCH subjects without any antihypertensive treatment (23 cohorts, 20 445 individuals), WCH subjects with antihypertensive treatment (11 cohorts, 8656 individuals), and mixed population including both treated and untreated subjects (12 cohorts, 21 336 individuals). This study revealed increased cardiovascular risk in untreated and mixed population WCH subjects but not in treated WCH subjects.

Summary

WCH might have prognostic impact on cardiovascular outcomes; however, this is not true in all WCH subjects. Further studies should identify the subgroups of WCH that are at increased risk and evaluate the effect of therapeutic measures on cardiovascular outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Kleinert HD, Harshfield GA, Pickering TG, Devereux RB, Sullivan PA, Marion RM, et al. What is the value of home blood pressure measurement in patients with mild hypertension? Hypertension. 1984;6:574–8.

    Article  CAS  PubMed  Google Scholar 

  2. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA. 1988;259:225–8.

    Article  CAS  PubMed  Google Scholar 

  3. O’Brien E, Parati G, Stergiou G, et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731–68.

    Article  PubMed  Google Scholar 

  4. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Zampi I, Gattobigio R, et al. White coat hypertension and white coat effect similarities and differences. Am J Hypertens. 1995;8:790–8.

    Article  CAS  PubMed  Google Scholar 

  5. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J. 2013;34:2159–219.

    Article  PubMed  Google Scholar 

  6. Martínez MA, García-Puig J, Martín JC, Guallar-Castillón P, Aguirre de Cárcer A, Torre A, et al. Frequency and determinants of white coat hypertension in mild to moderate hypertension: a primary care-based study. Monitorización Ambulatoria de la Presión Arterial (MAPA)-Area 5 Working Group. Am J Hypertens. 1999;12:251–9.

    Article  PubMed  Google Scholar 

  7. •• Franklin SS, Thijs L, Asayama K, et al. The cardiovascular risk of white-coat hypertension. J Am Coll Cardiol. 2016;68:2033–43. A large population-based cohort study that evaluated the cardiovascular risk of WCH.

    Article  PubMed  Google Scholar 

  8. Dolan E, Stanton A, Atkins N, Den Hond E, Thijs L, McCormack P, et al. Determinants of white-coat hypertension. Blood Press Monit. 2004;9:307–9.

    Article  CAS  PubMed  Google Scholar 

  9. Mancia G, Bertinieri G, Grassi G, Parati G, Pomidossi G, Ferrari A, et al. Effects of blood-pressure measurement by the doctor on patient’s blood pressure and heart rate. Lancet. 1983;2:695–8.

    Article  CAS  PubMed  Google Scholar 

  10. Grassi G, Turri C, Vailati S, Dell’Oro R, Mancia G. Muscle and skin sympathetic nerve traffic during the “white-coat” effect. Circulation. 1999;100:222–5.

    Article  CAS  PubMed  Google Scholar 

  11. Grassi G, Seravalle G, Buzzi S, Magni L, Brambilla G, Quarti-Trevano F, et al. Muscle and skin sympathetic nerve traffic during physician and nurse blood pressure measurement. J Hypertens. 2013;31:1131–5.

    Article  CAS  PubMed  Google Scholar 

  12. Jhalani J, Goyal T, Clemow L, Schwartz JE, Pickering TG, Gerin W. Anxiety and outcome expectations predict the white-coat effect. Blood Press Monit. 2005;10:317–9.

    Article  PubMed  Google Scholar 

  13. Spruill TM, Pickering TG, Schwartz JE, Mostofsky E, Ogedegbe G, Clemow L, et al. The impact of perceived hypertension status on anxiety and the white coat effect. Ann Behav Med. 2007;34:1–9.

    Article  PubMed  Google Scholar 

  14. Siegel WC, Blumenthal JA, Divine GW. Physiological, psychological, and behavioral factors and white coat hypertension. Hypertension. 1990;16:140–6.

    Article  CAS  PubMed  Google Scholar 

  15. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;31:1281–357.

    Article  CAS  PubMed  Google Scholar 

  16. Verdecchia P, Palatini P, Schillaci G, Mormino P, Porcellati C, Pessina AC. Independent predictors of isolated clinic (‘white-coat’) hypertension. J Hypertens. 2001;19:1015–20.

    Article  CAS  PubMed  Google Scholar 

  17. Manios ED, Koroboki EA, Tsivgoulis GK, Spengos KM, Spiliopoulou IK, Brodie FG, et al. Factors influencing white-coat effect. Am J Hypertens. 2008;21:153–8.

    Article  PubMed  Google Scholar 

  18. Fisher M, Blackwell J, Saseen J. Clinical inquiries. What is the best way to identify patients with white-coat hypertension? J Fam Pract. 2005;54(549–50):552.

    Google Scholar 

  19. Sega R, Cesana G, Milesi C, Grassi G, Zanchetti A, Mancia G. Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population. Hypertension. 1997;30:1–6.

    Article  CAS  PubMed  Google Scholar 

  20. Agyemang C, Bhopal R. Is the blood pressure of people from African origin adults in the UK higher or lower than that in European origin white people? A review of cross-sectional data. J Hum Hypertens. 2003;17:523–34.

    Article  PubMed  Google Scholar 

  21. Agyemang C, Bhopal R, Bruijnzeels M, Redekop WK. Does the white-coat effect in people of African and South Asian descent differ from that in White people of European origin? A systematic review and meta-analysis. Blood Press Monit. 2005;10:243–8.

    Article  PubMed  Google Scholar 

  22. Labinson PT, Giacco S, Gift H, Mansoor GA, White WB. The importance of the clinical observer in the development of a white-coat effect in African-American patients with hypertension. Blood Press Monit. 2008;13:139–42.

    Article  PubMed  Google Scholar 

  23. Staessen JA, Asmar R, De Buyzere M, Imai Y, Parati G, Shimada K, et al. Task Force II: blood pressure measurement and cardiovascular outcome. Blood Press Monit. 2001;6:355–70.

    Article  CAS  PubMed  Google Scholar 

  24. National Institute for Health and Clinical Excellence (NICE) (2011) The clinical management of primary hypertension in adults. UK: National Clinical Guideline Centre

  25. Lovibond K, Jowett S, Barton P, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet. 2011;378:1219–30.

    Article  PubMed  Google Scholar 

  26. O’Brien E, Asmar R, Beilin L, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003;21:301–6.

    Google Scholar 

  27. Hermida RC, Ayala DE, Fernández JR, Mojón A. Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction. Chronobiol Int. 2013;30:68–86.

    Article  PubMed  Google Scholar 

  28. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011;34:1270–6.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014;23:3–16.

    Article  PubMed  Google Scholar 

  30. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. JAMA. 2014;311:507.

    Article  CAS  PubMed  Google Scholar 

  31. Fagard RH, Staessen JA, Thijs L, et al. Relationship between ambulatory blood pressure and follow-up clinic blood pressure in elderly patients with systolic hypertension. J Hypertens. 2004;22:81–7.

    Article  CAS  PubMed  Google Scholar 

  32. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, et al. Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol. 2005;46:508–15.

    Article  PubMed  Google Scholar 

  33. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007;25:2193–8.

    Article  CAS  PubMed  Google Scholar 

  34. • Briasoulis A, Androulakis E, Palla M, Papageorgiou N, Tousoulis D. White-coat hypertension and cardiovascular events. J Hypertens. 2016;34:593–9. Meta-analysis evaluating the cardiovascular risk in subjects with WCH.

    Article  CAS  PubMed  Google Scholar 

  35. •• Huang Y, Huang W, Mai W, Cai X, An D, Liu Z, et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens. 2017;35:677–88. The largest meta-analysis evaluating the cardiovascular risk in WCH subjects.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. • Sivén SSE, Niiranen TJ, Kantola IM, Jula AM. White-coat and masked hypertension as risk factors for progression to sustained hypertension. J Hypertens. 2016;34:54–60. A population-based study evaluating the progression of WCH to sustained HTN over 11 years.

    Article  PubMed  Google Scholar 

  37. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Friz HP, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226–32.

    Article  CAS  PubMed  Google Scholar 

  38. de la Sierra A, Vinyoles E, Banegas JR, Segura J, Gorostidi M, de la Cruz JJ, Ruilope LM. Prevalence and clinical characteristics of white-coat hypertension based on different definition criteria in untreated and treated patients. J Hypertens. 2007;35:2388–2394.

  39. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47:846–53.

    Article  CAS  PubMed  Google Scholar 

  40. Mancia G, Facchetti R, Parati G, Zanchetti A. Effect of long-term antihypertensive treatment on white-coat hypertension. Hypertension. 2014;64:1388–98.

    Article  CAS  PubMed  Google Scholar 

  41. Fagard RH, Staessen JA, Thijs L, et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Circulation. 2000;102:1139–44.

    Article  CAS  PubMed  Google Scholar 

  42. Mancia G, Bombelli M, Brambilla G, Facchetti R, Sega R, Toso E, et al. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension. 2013;62:168–74.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mehran Abolbashari.

Ethics declarations

Conflict of Interest

Mehran Abolbashari declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Ischemic Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abolbashari, M. White Coat Hypertension and Cardiovascular Diseases: Innocent or Guilty. Curr Cardiol Rep 20, 25 (2018). https://doi.org/10.1007/s11886-018-0964-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-018-0964-0

Keywords

Navigation